|
Targeting AbcA1 and Ldlr production for the Discoveryof Alzheimers disease Drugs |
1R16GM145547-01 |
|
NIGMS |
2022 |
|
Effect of dietary restriction and exercise on behavioral outcomes and brain pathology in a transgenic model of Alzheimers disease |
2P20GM113109-06 |
|
NIGMS |
2022 |
|
Determining the role of a novel brainstem pathway in normal circadian function and in Alzheimers disease related dysfunction and sundowning-associated behavior |
2P20GM121310-06 |
|
NIGMS |
2022 |
|
Emerging imaging technologies for automated analyses of calcineurin-dependent brain function |
3R01GM136906-03S1 |
|
NIGMS |
2022 |
|
Quantitative 3D imaging of in situ nanoparticle movement and cellular behavior during neuroinflammation |
3R35GM124677-06S1 |
|
NIGMS |
2022 |
|
Regulation of microRNA-218 by TRIM9 in Alzheimers Disease and relhttps://apps.era.nih.gov/gmii/manage/view.era?applId=10497234#ated dementia |
3R35GM128753-05S1 |
|
NIGMS |
2022 |
|
Investigating structural heterogeneities in amyloid aggregates with multiscale infrared spectroscopic imaging |
3R35GM138162-03S1 |
|
NIGMS |
2022 |
|
Acquisition of a MICRON IV ocular imaging system |
3U54GM104941-10S1 |
|
NIGMS |
2022 |
|
Identification of novel methylation biomarkers in Alzheimers Disease |
5P20GM121325-05 |
|
NIGMS |
2022 |
|
Translational analysis of cerebrovascular dysfunction in aging |
5P20GM125528-04 |
|
NIGMS |
2022 |